Celltrion company profile
Company profile
Celltrion has 2,956 employees and is headquartered in Incheon, South Korea.
Patients in roughly 100 countries receive Celltrion's medicines, and the United States and Europe are among its main sales territories. The Incheon-based group develops, manufactures and sells biosimilars, which are copies of biologic drugs, for autoimmune diseases, cancers, osteoporosis, eye disorders and asthma. Its marketed brands include Remsima, Truxima, Herzuma, Yuflyma, Vegzelma, Omlyclo, Eydenzelt, Steqeyma, Stoboclo, Osenvelt, Avtozma and Zymfentra, along with Regkirona for COVID-19. Further candidates, including CT-P44 for multiple myeloma and CT-P53 for multiple sclerosis, are in Phase 3 clinical trials, and the pipeline also includes CT-G07 for HIV/AIDS.
Founded in 2002, the company is headquartered in Incheon, South Korea, and had 2,956 employees. In the fiscal year ended December 2025, revenue rose 17.0% to 4,162.5 billion won and net income reached 1,029.6 billion won.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- South Korea
- Headquarters
- 23, Academy-ro, Incheon
- Employees
- 2,956
- Founded
- 2002
- Fiscal year
- January - December
- Listing
- 068270 · KRX
- Currency
- KRW
- ISIN
- KR7068270008
- Website
- celltrion.com
Celltrion and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Celltrion068270 | South Korea | $36.53B | 2,956 | 31.6% | 31.4 |
| Samsung Biologics207940 | South Korea | $49.26B | 5,326 | 45.5% | 31.2 |
| WuXi Biologics (Cayman)2269 | Hong Kong SAR China | $24.29B | 14,705 | 32.4% | 35.1 |
| CSLCSL | Australia | $64.31B | 29,000 | 26.8% | — |
| Innovent Biologics1801 | Hong Kong SAR China | $18.84B | 8,754 | 7.4% | 111.5 |
| Sichuan Kelun-Biotech Biopharmaceutical6990 | Hong Kong SAR China | $13.65B | 2,300 | -0.2% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
